Hemoglobin H disease
MONDO:0013512Alpha thalassemia caused by variation in three of the four copies of the alpha hemoglobin genes (e.g., large deletion in HBA1 and HBA2 genes in trans with a variant in either HBA1 or HBA2).
Also known as: Alpha-thalassemia intermedia, HBA1;HBA2 digenic triallelic hemoglobin H disease, HBH, HbH, HbH disease, alpha-thalassemia intermedia, haemoglobin H disease, deletional and nondeletional, hemoglobin H disease
19 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New pill could boost red blood cells in thalassemia patients
Disease control OngoingThis phase 3 trial tests whether the drug mitapivat can improve anemia and reduce fatigue in people with alpha- or beta-thalassemia who do not need regular blood transfusions. About 194 participants received either mitapivat or a placebo daily for 24 weeks. The main goal is to se…
Phase: PHASE3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could a simple exercise routine strengthen bones in thalassemia?
Disease control OngoingThis trial investigates whether a 12- to 36-week program of aerobic and strength exercises can improve body composition, muscle function, and bone density in adolescents and adults with thalassemia. Participants will follow a self-directed routine of 30 minutes of exercise, 5 day…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New cord blood matching method could expand transplant access for blood cancer patients
Disease control OngoingThis study tests a new approach to stem cell transplants for people with blood cancers like leukemia and lymphoma. Patients receive a combination of umbilical cord blood and stem cells from a family member, with the cord blood chosen based on specific genetic markers rather than …
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 26, 2026 13:02 UTC
-
Tiny study probes Mitapivat's inner workings in sickle cell
Knowledge-focused OngoingThis observational study will examine how the drug mitapivat changes red blood cells in 6 people with sickle cell disease. Researchers will measure oxygen binding and cell survival markers from blood samples and muscle oxygen tests. The goal is to understand the drug's effects, n…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC